209 related articles for article (PubMed ID: 24639234)
1. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.
Xu H; Paxton J; Lim J; Li Y; Zhang W; Duxfield L; Wu Z
Pharm Res; 2014 Oct; 31(10):2583-92. PubMed ID: 24639234
[TBL] [Abstract][Full Text] [Related]
2. Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug.
Xu H; Paxton JW; Wu Z
Pharm Res; 2015 Jul; 32(7):2428-38. PubMed ID: 25663325
[TBL] [Abstract][Full Text] [Related]
3. pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells.
Bersani S; Vila-Caballer M; Brazzale C; Barattin M; Salmaso S
Eur J Pharm Biopharm; 2014 Nov; 88(3):670-82. PubMed ID: 25157908
[TBL] [Abstract][Full Text] [Related]
4. Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity.
Cai W; Geng C; Jiang L; Sun J; Chen B; Zhou Y; Yang B; Lu H
Pharm Dev Technol; 2020 Jun; 25(5):640-648. PubMed ID: 32028816
[TBL] [Abstract][Full Text] [Related]
5. Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine.
Xu H; Li Y; Paxton JW; Wu Z
Pharm Res; 2021 Jul; 38(7):1209-1219. PubMed ID: 34189639
[TBL] [Abstract][Full Text] [Related]
6. Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells.
Xu H; Paxton JW; Wu Z
Pharm Res; 2016 Jul; 33(7):1628-37. PubMed ID: 26964546
[TBL] [Abstract][Full Text] [Related]
7. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?
Tang M; Svirskis D; Leung E; Kanamala M; Wang H; Wu Z
J Control Release; 2019 Jul; 305():89-100. PubMed ID: 31096017
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
9. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes.
Calvagno MG; Celia C; Paolino D; Cosco D; Iannone M; Castelli F; Doldo P; Frest M
Curr Drug Deliv; 2007 Jan; 4(1):89-101. PubMed ID: 17269921
[TBL] [Abstract][Full Text] [Related]
10. Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its self-assembled nanoparticles.
Daman Z; Ostad S; Amini M; Gilani K
Int J Pharm; 2014 Jul; 468(1-2):142-51. PubMed ID: 24731731
[TBL] [Abstract][Full Text] [Related]
11. Development of Liposomal Gemcitabine with High Drug Loading Capacity.
Tamam H; Park J; Gadalla HH; Masters AR; Abdel-Aleem JA; Abdelrahman SI; Abdelrahman AA; Lyle LT; Yeo Y
Mol Pharm; 2019 Jul; 16(7):2858-2871. PubMed ID: 31136710
[TBL] [Abstract][Full Text] [Related]
12. Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer.
Daman Z; Montazeri H; Azizi M; Rezaie F; Ostad SN; Amini M; Gilani K
Pharm Res; 2015 Nov; 32(11):3756-67. PubMed ID: 26228105
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases.
Cosco D; Paolino D; Cilurzo F; Casale F; Fresta M
Int J Pharm; 2012 Jan; 422(1-2):229-37. PubMed ID: 22093954
[TBL] [Abstract][Full Text] [Related]
14. Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
Deodhar S; Dash AK; North EJ; Hulce M
AAPS PharmSciTech; 2020 Aug; 21(6):231. PubMed ID: 32778980
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine hydrochloride-loaded liposomes and nanoparticles: comparison of encapsulation efficiency, drug release, particle size, and cytotoxicity.
Yalcin TE; Ilbasmis-Tamer S; Ibisoglu B; Özdemir A; Ark M; Takka S
Pharm Dev Technol; 2018 Jan; 23(1):76-86. PubMed ID: 28724327
[TBL] [Abstract][Full Text] [Related]
16. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.
Bornmann C; Graeser R; Esser N; Ziroli V; Jantscheff P; Keck T; Unger C; Hopt UT; Adam U; Schaechtele C; Massing U; von Dobschuetz E
Cancer Chemother Pharmacol; 2008 Mar; 61(3):395-405. PubMed ID: 17554540
[TBL] [Abstract][Full Text] [Related]
17. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.
Öztürk K; Esendağlı G; Gürbüz MU; Tülü M; Çalış S
Int J Pharm; 2017 Jan; 517(1-2):157-167. PubMed ID: 27965135
[TBL] [Abstract][Full Text] [Related]
18. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
19. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific delivery of gemcitabine with activatable liposomes.
Tucci ST; Kheirolomoom A; Ingham ES; Mahakian LM; Tam SM; Foiret J; Hubbard NE; Borowsky AD; Baikoghli M; Cheng RH; Ferrara KW
J Control Release; 2019 Sep; 309():277-288. PubMed ID: 31301340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
